The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Wyndrum - So you don't have any evidence. In my view you have a very distorted view of a LTH. Of course people are going to react to both positive and negative news from a company. That does not make them a trader in my book. It is obvious you use charts to try and predict the movement up or down of Avacta on a daily basis. That is a trader.
Ndn - What utter rubbish! No way would they have got this passage in the RNS of 10 May past the Nomad if it wasn't fact.
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the Declaration of Conformity for CE mark of its AffiDX® SARS-CoV-2 antigen rapid test for professional use has been submitted to the Medicines and Healthcare products Regulatory Agency ("MHRA") through the Group's partner Mologic Limited.